Screener
Cullinan Therapeutics, Inc. CGEM Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Cullinan Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Cullinan Therapeutics, Inc.’s 10-K, filed March 10, 2026.
- Filed
- Mar 10, 2026, 7:26 AM EDT
- Fiscal year
- FY2025
- Accession
- 0001193125-26-099362
| Line item | December 31, 2025 | December 31, 2024 |
|---|---|---|
| Common stock, $0.0001 par value, 150,000,000 shares authorized as of December 31, 2025 and 2024; 60,244,136 and 58,510,610 shares issued and outstanding as of December 31, 2025 and 2024, respectively. | 6 | 6 |
| Additional paid-in capital | 995,823 | 958,695 |
| Accumulated other comprehensive gain (loss) | 1,020 | (133) |
| Accumulated deficit | (588,119) | (368,240) |
| Total Cullinan stockholders' equity | 408,730 | 590,328 |
| Noncontrolling interests | — | — |
| Total stockholders' equity | 408,730 | 590,328 |
| Total liabilities and stockholders' equity | $448,374 | $621,824 |
Item 16. Form 10-K Summary.
FAQ
- What is Cullinan Therapeutics, Inc.'s total equity?
- Cullinan Therapeutics, Inc. (CGEM) reported total equity of $408.73M in Q4 2025.
- How has Cullinan Therapeutics, Inc.'s total equity changed year-over-year?
- Cullinan Therapeutics, Inc.'s total equity decreased by 30.8% year-over-year, from $590.33M to $408.73M.
- What is the long-term trend for Cullinan Therapeutics, Inc.'s total equity?
- Over 5 years (2020 to 2025), Cullinan Therapeutics, Inc.'s total equity has grown at a 15.5% compound annual growth rate (CAGR), from $199.01M to $408.73M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Cullinan Therapeutics, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude